Cargando…
A LRRK2 GTP Binding Inhibitor, 68, Reduces LPS-Induced Signaling Events and TNF-α Release in Human Lymphoblasts
Mutations in the leucine-rich repeat kinase-2 (LRRK2) gene cause autosomal-dominant Parkinson’s disease (PD) and contribute to sporadic PD. Common genetic variation in LRRK2 modifies susceptibility to immunological disorders including Crohn’s disease and leprosy. Previous studies have reported that...
Autores principales: | Li, Tianxia, Ning, Bo, Kong, Lingbo, Dai, Bingling, He, Xiaofei, Thomas, Joseph M., Sawa, Akira, Ross, Christopher A., Smith, Wanli W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7926966/ https://www.ncbi.nlm.nih.gov/pubmed/33672296 http://dx.doi.org/10.3390/cells10020480 |
Ejemplares similares
-
A Novel GTP-Binding Inhibitor, FX2149, Attenuates LRRK2 Toxicity in Parkinson’s Disease Models
por: Li, Tianxia, et al.
Publicado: (2015) -
LRRK2 Kinase Activity Is Dependent on LRRK2 GTP Binding Capacity but Independent of LRRK2 GTP Binding
por: Taymans, Jean-Marc, et al.
Publicado: (2011) -
68 and FX2149 Attenuate Mutant LRRK2-R1441C-Induced Neural Transport Impairment
por: Thomas, Joseph M., et al.
Publicado: (2017) -
Models for LRRK2-Linked Parkinsonism
por: Li, Tianxia, et al.
Publicado: (2011) -
GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2
por: Blanca Ramírez, Marian, et al.
Publicado: (2017)